The OncLive Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.
Dr. Michael Lim on Toxicities of Checkpoint InhibitorsNovember 23rd 2015
Michael Lim, MD, Director of Brain Tumor Immunotherapy, Associate Professor of Neurosurgery, Johns Hopkins Medicine, discusses toxicities associated with checkpoint inhibitors for the treatment of glioblastoma.
'Groundbreaking' Global Brain Cancer Trial PlannedNovember 22nd 2015
An international coalition of experts is planning an innovative clinical trial aimed at speeding up the development of new treatments for patients with glioblastoma multiforme, putting into motion a biomarker-driven approach that has been employed in other malignancies.
Dr. Okada Discusses Immunotherapy Response Assessment in Neuro-OncologyNovember 22nd 2015
Hideho Okada MD, PhD, discusses the need for a new immunotherapy response assessment in euro-oncology. Okada presented on this topic at the 2015 Annual Meeting of the Society for Neuro-Oncology.
Rindopepimut Combo Continues to Show Strong OS Benefit in Relapsed GBM
Treatment with the immunotherapy rindopepimut plus bevacizumab resulted in a 47% reduction in the risk of death compared with bevacizumab and a control for patients with relapsed glioblastoma multiforme.
Promising Subgroup Data Leads to Phase III Immunotherapy Study for GBMNovember 21st 2015
Findings from a subgroup of patients enrolled in a phase II study assessing the dendritic vaccine ICT-107 for patients with HLA-A2+ glioblastoma multiforme merit further exploration in a phase III study.
Testing Checkpoint Inhibitors in Brain Cancer Requires Careful AE ManagementNovember 20th 2015
As immunotherapy begins to be studied across central nervous system tumors it becomes increasingly important for practitioners to understanding the unique adverse event profiles associated with these agents.
Dr. Piccioni on Tumor Profiles of Brain MetastasesSeptember 2nd 2015
David Piccioni, MD, PhD, assistant professor, Neuroscience and Neuro-Oncology, UC San Diego Health, discusses tumor profiling of brain metastases of patients with non-small cell lung cancer, breast cancer, and melanoma.
Blocking the PD-1/PD-L1 Signaling Pathway in Malignant Glioma: Current and Future PerspectivesAugust 9th 2015
Blockade of the PD-1/PD-L1 pathway is a novel and attractive treatment approach to many cancers, including malignant glioma, because of its potential to restore anti-tumor immunity.
Dr. Michalski on Minimizing Long-Term Consequences of RadiationMay 5th 2015
Jeff Michalski, MD, professor, vice chair of Radiation Oncology, Washington University School of Medicine, Siteman Cancer Center explains the importance of minimizing the long-term consequences of radiation.
Dr. Daniel Brat on Characterizing Diffuse Lower Grade GliomasApril 27th 2015
Daniel J. Brat, MD, PhD, vice chair, Translational Programs, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, director, Cancer Tissue and Pathology Shared Resource, Winship Cancer Institute, discusses genomic characterization of diffuse lower grade gliomas.
FDA Grants Rindopepimut Breakthrough Designation for EGFRvIII-Positive GlioblastomaFebruary 23rd 2015
Rindopepimut (Rintega) has gained a Breakthrough Therapy Designation from the FDA to treat adult patients with glioblastoma multiforme that test positive for the epidermal growth factor receptor variant.